TP53 and familial pancreatic carcinoma: The HMG-CoA reductase inhibitory statin drug 33 (Figure 5, atorvastatin), which is applied for the treatment of cardiovascular disease based on its cholesterol depletion activity, was also studied for its inhibition of DNAJA1 farnesylation in pancreatic cancer cells expressing wild-type or mutant p53 proteins [132].